Concomitant Interstitial Lung Disease with Psoriasis

Table 2

Demographic and clinical features of 21 ILD patients with psoriasis.

Patient	Age/sex	Arthritis	Autoimmune disease/marker	Prior/concomitant immunosuppressants	Clinical diagnosis	Radiographic diagnosis	ILD stage	Pathology	Outcome
1	68/M	No	SSA (+)	No	IPF	UIP pattern^#	Limited	Not obtained	Survived at 3 months
2	66/M	No	No	No	RBILD/DIP	RBILD/DIP pattern	Limited	RBILD/DIP pattern	Survived at 34 months
3	52/M	Yes	PM/DM CREST	No	CTD-ILD	NSIP pattern	Limited	OP/EP pattern	Survived at 56 months
4	80/M	No	No	No	COP	OP pattern	Limited	OP/EP pattern	Survived at 13 months
5	78/M	No	No	No	IPF	UIP pattern	Limited	Not obtained	Survived at 51 months
6	46/M	Yes	No	MTX, etanercept	IPF/IgG4-related lung disease	NSIP/OP pattern	Limited	Not obtained	Survived at 11 months
7	58/F	Yes	No	Hydroxychloroquine sulfate, MTX, infliximab	NSIP	NSIP/OP pattern	Limited	Not obtained	Survived at 3 months
8	76/M	No	No	No	IPF	UIP pattern	Extensive	Not obtained	Unknown
9	49/M	No	No	No	IPF	UIP pattern	Limited	Not obtained	Survived at 23 months
10	60/M	No	ANCA (+)	No	CHP	OP/HP pattern	Extensive	Early UIP/OP	Survived at 8 months
11	62/M	No	No	No	NSIP	NSIP pattern	Extensive	Not obtained	Survived at 48 months
12	81/F	No	No	6-MP	COP	NSIP pattern	Limited	Not obtained	Died at 13 months
13	80/F	No	ANCA (+)	Azathioprine	IPF	UIP pattern	Limited	Not obtained	Survived at 1 month
14	63/M	No	No	No	IPF	UIP pattern	Limited	Not obtained	Survived at 46 months
15	48/M	No	No	No	IPF	NSIP pattern	Extensive	Not obtained	Survived at 18 months
16	53/F	No	No	No	Mitral valve lung disease	Reticular and GGO in lung bases with innumerable small nodules	Limited	Not obtained	Survived at 17 months
17	67/M	No	No	MTX, etanercept	IPF	UIP pattern	Extensive	Not obtained	Survived at 4 months
18	62/F	No	No	Chemotherapy for breast cancer	IPF	UIP pattern	Extensive	Not obtained	Survived at 12 months
19	86/F	No	No	No	IPF	UIP pattern	Extensive	Not obtained	Died at 8 months
20	79/M	No	No	Chemotherapy for lymphoma	Unspecific	Mosaic attenuation	Limited	Not obtained	Survived at 53 months
21	69/F	Yes	No	MTX, etanercept sulfasalazine	CHP	HP pattern	Limited	Not obtained	Survived at 4 months

ANA: antinuclear antibody, ANCA: antineutrophil cytoplasmic antibody, CHP: chronic hypersensitivity pneumonitis, COP: cryptogenic organizing pneumonia, CTD-ILD: connective tissue disease-associated interstitial lung disease, EP: eosinophilic pneumonia, F: female, GGO: ground glass opacities, HP: hypersensitivity pneumonitis, IPF: idiopathic pulmonary fibrosis, M: male, MP: mercaptpurine, MTX: methotrexate, NSIP: nonspecific interstitial pneumonia, OP: organizing pneumonia, PE: pulmonary embolus, PM/DM: polymyositis/dermatomyositis, RBILD/DIP: respiratory bronchiolitis-associated interstitial lung disease/desquamative interstitial pneumonia, SSA: SS-A antibody, and UIP: usual interstitial pneumonia. A staging system, originally proposed for ILD with systemic sclerosis, by Goh et al. [11]. Patient had a mild elevation of serum SS-A (1.20 AI) but lacked sicca symptom and other symptoms suggestive of underlying autoimmune disease (i.e., arthralgia, digital fissuring/ulceration, and Raynaud’s phenomenon). Patients had positivity of serum ANCA but lacked clinical symptom suggestive of underlying systemic vasculitis (i.e., skin rash, alveolar haemorrhage, and glomerulonephritis). ^#We defined both radiological “definitive UIP pattern” and “probable UIP pattern” as “UIP pattern” in the present study.